The estimated Net Worth of Edward Miller is at least $1.02 Milion dollars as of 19 August 2024. Mr Miller owns over 422 units of AlloVir stock worth over $164,146 and over the last 10 years he sold ALVR stock worth over $850,968.
Mr has made over 23 trades of the AlloVir stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 422 units of ALVR stock worth $321 on 19 August 2024.
The largest trade he's ever made was selling 8,869 units of AlloVir stock on 5 February 2024 worth over $5,942. On average, Mr trades about 1,148 units every 105 days since 2014. As of 19 August 2024 he still owns at least 215,981 units of AlloVir stock.
You can see the complete history of Mr Miller stock trades at the bottom of the page.
Edward Miller is the Gen. Counsel & Sec. at AlloVir.
Mr Miller is 56, he's been the Gen. Counsel & Sec. of AlloVir since . There are 4 older and 4 younger executives at AlloVir. The oldest executive at AlloVir, Inc. is Vikas Sinha C.A., CPA, M.B.A., 58, who is the Pres, CFO & Director.
Edward's mailing address filed with the SEC is C/O ALLOVIR, INC., P.O. BOX 44, 1661 MASSACHUSETTS AVE., LEXINGTON, MA, 02420.
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... a Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
AlloVir executives and other stock owners filed with the SEC include: